Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery

This trial is to investigate if in patients with clinically node positive breast cancer undergoing upfront surgery, treatment with TAS and ART is superior to ALND in terms of arm-related Quality of Life (QoL) and occurrence of lymphedema two years after randomization.

Trial Details

NCT ID
NCT07140172
Phase
NA
Sponsor
University Hospital, Basel, Switzerland
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Axillary lymph node dissection (ALND)
  • Axillary radiotherapy (ART)
Locations (sample)
  • Bethesda, Maryland, United States|38.98067,-77.10026
  • Durham, North Carolina, United States|35.99403,-78.89862
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362
  • Seattle, Washington, United States|47.60621,-122.33207
  • Dornbirn, Austria|47.41427,9.74195

Key Eligibility Criteria

  • Written informed consent according to ICH/GCP regulations prior to any trial specific procedures.
  • Patients ≥ 18 years of age.
  • Node-positive breast cancer (histologically or cytologically proven both in primary tumor and in lymph node) American Joint Committee on Cancer/ In…
  • Node-positivity detected by imaging and non-palpable (iN+) and confirmed by pathology.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →